Antineoplastic Agents, Alkylating
"Antineoplastic Agents, Alkylating" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)
| Descriptor ID |
D018906
|
| MeSH Number(s) |
D27.505.519.124.035 D27.505.954.248.150 D27.888.569.035.035
|
| Concept/Terms |
Antineoplastic Agents, Alkylating- Antineoplastic Agents, Alkylating
- Alkylating Antineoplastic Agents
- Alkylating Antineoplastic Drugs
- Alkylating Antineoplastics
- Antineoplastic Alkylating Agents
- Antineoplastic Drugs, Alkylating
- Antineoplastics, Alkylating
- Alkylating Agents, Antineoplastic
- Alkylating Drugs, Antineoplastic
- Antineoplastic Alkylating Drugs
- Drugs, Antineoplastic Alkylating
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents, Alkylating".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents, Alkylating".
This graph shows the total number of publications written about "Antineoplastic Agents, Alkylating" by people in this website by year, and whether "Antineoplastic Agents, Alkylating" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 0 | 1 |
| 1999 | 1 | 0 | 1 |
| 2000 | 1 | 1 | 2 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 2 | 0 | 2 |
| 2004 | 3 | 1 | 4 |
| 2005 | 3 | 1 | 4 |
| 2006 | 4 | 1 | 5 |
| 2007 | 2 | 1 | 3 |
| 2008 | 1 | 3 | 4 |
| 2009 | 2 | 1 | 3 |
| 2010 | 0 | 2 | 2 |
| 2011 | 1 | 1 | 2 |
| 2013 | 4 | 1 | 5 |
| 2014 | 3 | 3 | 6 |
| 2015 | 4 | 4 | 8 |
| 2016 | 2 | 1 | 3 |
| 2017 | 0 | 1 | 1 |
| 2019 | 0 | 2 | 2 |
| 2020 | 2 | 3 | 5 |
| 2021 | 1 | 2 | 3 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antineoplastic Agents, Alkylating" by people in Profiles.
-
Revisiting intrathecal thiotepa: Efficacy and safety in secondary CNS malignancies. Med Oncol. 2024 Jun 17; 41(7):177.
-
An expanded-access clinical study of thiotepa (DSP-1958) high-dose chemotherapy before autologous hematopoietic stem cell transplantation in patients with malignant lymphoma. Int J Hematol. 2022 Mar; 115(3):391-398.
-
Disease Control and Patterns of Failure After Proton Beam Therapy for Rhabdomyosarcoma. Int J Radiat Oncol Biol Phys. 2021 03 01; 109(3):718-725.
-
Multicentric non-enhancing lesions in glioblastoma: A retrospective study. J Clin Neurosci. 2021 Mar; 85:20-26.
-
Management of Waldenstr?m macroglobulinemia in 2020. Hematology Am Soc Hematol Educ Program. 2020 12 04; 2020(1):372-379.
-
What lies beneath: Cutaneous involvement of mantle cell lymphoma underlying an insect-bite-like reaction. J Cutan Pathol. 2021 Apr; 48(4):563-566.
-
An unusual case of cutaneous Waldenstr?m macroglobulinemia with the MYD88 L265P mutation. J Cutan Pathol. 2020 Sep; 47(9):850-853.
-
Incorporation of thiotepa in a reduced intensity conditioning regimen may improve engraftment after transplant for HLH. Br J Haematol. 2020 03; 188(6):e84-e87.
-
Outcomes of bendamustine- or cyclophosphamide-based first-line chemotherapy in older patients with indolent B-cell lymphoma. Am J Hematol. 2020 04; 95(4):354-361.
-
Treatment strategies for glioblastoma in older patients: age is just a number. J Neurooncol. 2019 Nov; 145(2):357-364.